Investor Relations

Corporate Profile

BiomX is a clinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

NYSEAM: PHGE

$8.05
Price
$0.55 7.33%
Change
12,833
Volume
183.82
Market Cap $M

Contact Information

7 Pinhas Sapir St. Floor 2,
Ness Ziona 7414002, Israel
Arrow